Previously, a study reported that tTMB correlates with bTMB and bTMB helps to identify patients who derive clinically significant improvements in PFS from atezolizumab in second-line or posterior treatment in NSCLC [19]. This evidence concerns the gene TMEM200B and non-small cell lung carcinoma.